EMEND TRI-PACK DIN 02298813
Health Canada record
| Active ingredient(s) | APREPITANT 125 MG; APREPITANT 80 MG |
|---|---|
| Dosage form | Capsule; Kit |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A04AD12 APREPITANT |
| Original market date | 24-Sep-2007 |
| Current status date | 24-Sep-2007 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing APREPITANT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02298805 | EMEND | MERCK CANADA INC | Capsule | APREPITANT 125 MG | Marketed |
| 02298791 | EMEND | MERCK CANADA INC | Capsule | APREPITANT 80 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 8991 | 2007-08-24 | New Drug Submission (NDS) |
International API supply for APREPITANT
6 valid EDQM Certificates of Suitability from 6 holders. 37 active FDA Drug Master Files.
Request a quote for EMEND TRI-PACK